Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Employment | 1 | 2021 | 45 | 0.740 |
Why?
|
| Medication Adherence | 1 | 2021 | 46 | 0.720 |
Why?
|
| Veterans | 1 | 2021 | 66 | 0.700 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 80 | 0.700 |
Why?
|
| Brain Ischemia | 3 | 2022 | 80 | 0.520 |
Why?
|
| Pancreatic Neoplasms | 4 | 2022 | 506 | 0.510 |
Why?
|
| Stroke | 3 | 2021 | 233 | 0.430 |
Why?
|
| Firefighters | 2 | 2022 | 7 | 0.400 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 2 | 2022 | 9 | 0.400 |
Why?
|
| Air Pollutants, Occupational | 2 | 2022 | 11 | 0.400 |
Why?
|
| Occupational Exposure | 2 | 2022 | 25 | 0.390 |
Why?
|
| Cachexia | 2 | 2022 | 51 | 0.380 |
Why?
|
| Diabetes, Gestational | 2 | 2022 | 63 | 0.360 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2022 | 54 | 0.360 |
Why?
|
| Humans | 26 | 2022 | 26749 | 0.320 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 207 | 0.290 |
Why?
|
| Interferon-beta | 2 | 2022 | 40 | 0.240 |
Why?
|
| Hydrocephalus | 2 | 2022 | 51 | 0.240 |
Why?
|
| Thrombectomy | 2 | 2020 | 26 | 0.220 |
Why?
|
| Amino Acids | 2 | 2022 | 80 | 0.210 |
Why?
|
| Metabolomics | 2 | 2022 | 79 | 0.210 |
Why?
|
| Parabens | 1 | 2022 | 5 | 0.210 |
Why?
|
| Acetate-CoA Ligase | 1 | 2022 | 8 | 0.210 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2022 | 38 | 0.200 |
Why?
|
| Lung Injury | 1 | 2022 | 31 | 0.200 |
Why?
|
| Communicable Diseases | 1 | 2022 | 19 | 0.200 |
Why?
|
| Influenza A virus | 1 | 2022 | 29 | 0.200 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2022 | 31 | 0.190 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2022 | 42 | 0.190 |
Why?
|
| Antigens, CD | 1 | 2022 | 134 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 77 | 0.190 |
Why?
|
| Fires | 1 | 2021 | 10 | 0.190 |
Why?
|
| Pneumonia | 1 | 2022 | 89 | 0.190 |
Why?
|
| Arsenicals | 1 | 2021 | 5 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 145 | 0.190 |
Why?
|
| MicroRNAs | 2 | 2022 | 280 | 0.190 |
Why?
|
| Hyperglycemia | 1 | 2022 | 77 | 0.190 |
Why?
|
| Influenza, Human | 1 | 2022 | 84 | 0.190 |
Why?
|
| Arsenic | 1 | 2021 | 19 | 0.190 |
Why?
|
| Cell Plasticity | 1 | 2021 | 9 | 0.190 |
Why?
|
| Adenosine | 1 | 2021 | 33 | 0.190 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 61 | 0.180 |
Why?
|
| Solute Carrier Organic Anion Transporter Family Member 1B3 | 1 | 2021 | 16 | 0.180 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 117 | 0.180 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2021 | 26 | 0.180 |
Why?
|
| Cell Line, Tumor | 5 | 2022 | 1256 | 0.180 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 131 | 0.180 |
Why?
|
| Mental Health | 1 | 2021 | 96 | 0.180 |
Why?
|
| Endometrial Neoplasms | 1 | 2022 | 180 | 0.180 |
Why?
|
| Cigarette Smoking | 1 | 2022 | 76 | 0.180 |
Why?
|
| Zinc | 1 | 2021 | 56 | 0.180 |
Why?
|
| Hepatocytes | 1 | 2021 | 68 | 0.180 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 110 | 0.180 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2019 | 4 | 0.170 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 115 | 0.170 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 116 | 0.170 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2019 | 16 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 26 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 284 | 0.170 |
Why?
|
| Disease Management | 1 | 2020 | 84 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 160 | 0.170 |
Why?
|
| Pilot Projects | 4 | 2022 | 385 | 0.170 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 60 | 0.160 |
Why?
|
| Cell Movement | 1 | 2021 | 352 | 0.160 |
Why?
|
| Smokers | 1 | 2020 | 124 | 0.160 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 122 | 0.160 |
Why?
|
| DNA Damage | 1 | 2019 | 149 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2022 | 466 | 0.150 |
Why?
|
| Models, Biological | 1 | 2021 | 446 | 0.150 |
Why?
|
| Biomarkers | 4 | 2022 | 731 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 339 | 0.150 |
Why?
|
| Liver | 1 | 2021 | 414 | 0.150 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 399 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 276 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2021 | 511 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 798 | 0.140 |
Why?
|
| Brain | 1 | 2021 | 693 | 0.130 |
Why?
|
| Female | 8 | 2022 | 14405 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 563 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2022 | 1217 | 0.110 |
Why?
|
| Neoplasms | 1 | 2022 | 748 | 0.110 |
Why?
|
| Mice | 4 | 2022 | 4393 | 0.100 |
Why?
|
| Muscles | 2 | 2022 | 70 | 0.100 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 37 | 0.100 |
Why?
|
| Cerebral Infarction | 2 | 2022 | 26 | 0.090 |
Why?
|
| Risk Factors | 3 | 2022 | 2008 | 0.090 |
Why?
|
| Animals | 5 | 2022 | 9927 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2022 | 2426 | 0.090 |
Why?
|
| Male | 6 | 2022 | 12826 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2021 | 2262 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2022 | 701 | 0.080 |
Why?
|
| Lung | 2 | 2022 | 349 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 473 | 0.080 |
Why?
|
| Middle Aged | 4 | 2021 | 6792 | 0.080 |
Why?
|
| Pregnancy | 2 | 2022 | 1126 | 0.070 |
Why?
|
| Prognosis | 2 | 2020 | 759 | 0.070 |
Why?
|
| Phenol | 1 | 2022 | 7 | 0.050 |
Why?
|
| Dynamin II | 1 | 2022 | 12 | 0.050 |
Why?
|
| Tumor Necrosis Factors | 1 | 2022 | 14 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 20 | 0.050 |
Why?
|
| Dextrans | 1 | 2022 | 22 | 0.050 |
Why?
|
| Syndecan-1 | 1 | 2022 | 12 | 0.050 |
Why?
|
| Phenols | 1 | 2022 | 24 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2022 | 40 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2022 | 23 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2022 | 81 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2022 | 6 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2022 | 33 | 0.050 |
Why?
|
| Integrins | 1 | 2022 | 27 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 90 | 0.050 |
Why?
|
| Blood Volume | 1 | 2022 | 8 | 0.050 |
Why?
|
| Environmental Monitoring | 1 | 2022 | 62 | 0.050 |
Why?
|
| Sphingolipids | 1 | 2022 | 20 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2022 | 38 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 71 | 0.050 |
Why?
|
| Lysosomes | 1 | 2022 | 54 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2022 | 83 | 0.050 |
Why?
|
| Tobacco | 1 | 2022 | 86 | 0.050 |
Why?
|
| China | 1 | 2021 | 53 | 0.050 |
Why?
|
| Research | 1 | 2022 | 87 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 36 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 99 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 2021 | 36 | 0.050 |
Why?
|
| Cacodylic Acid | 1 | 2021 | 5 | 0.050 |
Why?
|
| Methylation | 1 | 2021 | 21 | 0.050 |
Why?
|
| Sincalide | 1 | 2021 | 4 | 0.050 |
Why?
|
| Language | 1 | 2021 | 61 | 0.050 |
Why?
|
| Lipids | 1 | 2022 | 195 | 0.050 |
Why?
|
| Integrin alpha3 | 1 | 2021 | 18 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2022 | 90 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 67 | 0.050 |
Why?
|
| Transcriptome | 1 | 2022 | 199 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2021 | 93 | 0.050 |
Why?
|
| Brain Infarction | 1 | 2020 | 10 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 56 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2021 | 65 | 0.050 |
Why?
|
| ROC Curve | 1 | 2021 | 139 | 0.050 |
Why?
|
| Proteomics | 1 | 2022 | 177 | 0.050 |
Why?
|
| Rats, Wistar | 1 | 2021 | 145 | 0.050 |
Why?
|
| Spheroids, Cellular | 1 | 2021 | 52 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 213 | 0.050 |
Why?
|
| Infarction | 1 | 2020 | 8 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 180 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2021 | 107 | 0.040 |
Why?
|
| Cation Transport Proteins | 1 | 2021 | 54 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 277 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 151 | 0.040 |
Why?
|
| Vasospasm, Intracranial | 1 | 2020 | 14 | 0.040 |
Why?
|
| Aged | 2 | 2020 | 5154 | 0.040 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2020 | 26 | 0.040 |
Why?
|
| Histone Deacetylase 1 | 1 | 2019 | 10 | 0.040 |
Why?
|
| Histone Deacetylase 2 | 1 | 2019 | 10 | 0.040 |
Why?
|
| Survivors | 1 | 2020 | 36 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 36 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 45 | 0.040 |
Why?
|
| African Americans | 1 | 2022 | 348 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 368 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 53 | 0.040 |
Why?
|
| Carotid Artery, Internal | 1 | 2019 | 19 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 249 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 379 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2021 | 134 | 0.040 |
Why?
|
| Middle Cerebral Artery | 1 | 2019 | 48 | 0.040 |
Why?
|
| Acute Disease | 1 | 2020 | 156 | 0.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 125 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 90 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 446 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 263 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2022 | 762 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 469 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2019 | 558 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 400 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 443 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 439 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 594 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 980 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 713 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 1469 | 0.040 |
Why?
|
| Smoking | 1 | 2020 | 465 | 0.030 |
Why?
|
| Child | 1 | 2022 | 2134 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2020 | 605 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 1925 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 1335 | 0.030 |
Why?
|
| Adult | 1 | 2020 | 7352 | 0.020 |
Why?
|